Lungs Heart The phase 3 EMPEROR-Preserved trial assessed empagliflozin in 5988 adults with heart failure with preserved ejection fraction, with and without diabetes. Full results from the phase 3 ...

Empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) provides a wide range of benefits in patients with “true” heart failure and preserved ejection fraction (HFpEF) , meaning an LVEF of 50% or ...

Please provide your email address to receive an email when new articles are posted on . WASHINGTON — Patients with acute HF assigned the SGLT2 inhibitor empagliflozin saw a greater improvement in HF ...

The EMPEROR-Preserved trial compared the efficacy and safety of empagliflozin with placebo in adults with heart failure and preserved ejection fraction, with and without diabetes. Treatment with ...

Empagliflozin on top of guideline recommended therapy improved CV and renal outcomes in HF with reduced ejection fraction, regardless of whether the cause of HF was ischemic or not, a study found. The ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Treatment with ...

EMPEROR-Preserved represents the first trial to show unequivocal benefits of any drug on major heart failure outcomes in patients with heart failure and preserved ejection fraction, the lead ...

Patients hospitalized for acute heart failure and prescribed empagliflozin saw improvements in quality of life at 15 and 90 days post-discharge. The study may make the case for prescribing SGLT2 ...

Patients with acute heart failure were safely started on empagliflozin (Jardiance; Boehringer Ingelheim/Eli Lilly) a median of 3 days after hospitalization and were 36% more likely to “experience a ...

Compared with monotherapy, finerenone plus empagliflozin was associated with improved kidney outcomes in T2D and CKD regardless of GLP-1RA use. Compared with monotherapy and regardless of prior ...

Empagliflozin is currently indicated for the treatment of adults with insufficiently controlled type 2 diabetes. 6,7,8 Additionally, empagliflozin is approved for the treatment of adults with heart ...

The EMPEROR-Preserved trial compared the efficacy and safety of empagliflozin with placebo in adults with heart failure and preserved ejection fraction, with and without diabetes. Treatment with ...